The soy peptide lunasin is showing success in treating metastatic colon cancer, according to a Cancer Letters report.
Researchers at the University of Illinois found that lunasin binds to a specific receptor in highly metastatic colon cancer cells, preventing them from attaching to the liver. Almost all colon cancer deaths involve the cancer spreading to the liver.
Specifically, combining lunasin with the chemotherapy drug oxaliplatin resulted in a six-fold reduction in the number of new tumor sites.
Related Articles on Colon Cancer:
High Levels of Alcohol Consumption Increase Risk of Colon Cancer
Study: MRI Helps Predict Survival of Rectal Cancer Patients
First Endoscopic Suturing Performed on Large Polyp Resection